The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
p53-A natural cancer killer: Structural insights and therapeutic concepts
Abstract
Every single day, the DNA of each cell in the human body is mutated thousands of times, even in absence of oncogenes or extreme radiation. Many of these mutations could lead to cancer and, finally, death. To fight this, multicellular organisms have evolved an efficient control system with the tumor‐suppressor protein p53 as the central element. An intact p53 network ensures that DNA damage is detected early on. The importance of p53 for preventing cancer is highlighted by the fact that p53 is inactivated in more than 50 % of all human tumors. Thus, for good reason, p53 is one of the most intensively studied proteins. Despite the great effort that has been made to characterize this protein, the complex function and the structural properties of p53 are still only partially known. This review highlights basic concepts and recent progress in understanding the structure and regulation of p53, focusing on emerging new mechanistic and therapeutic concepts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53 is a homotetramer, with folded tetramerization and core domains that are linked together and flanked by intrinsically disordered (or natively unfolded) domains at the N and C termini (1, 2).”
From Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Coupling of folding and binding for unstructured proteins
Dyson, H. J., & Wright, P. E. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00289-0 · Cited by 1,327
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679
Structure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
Cancer and ageing: rival demons?
Campisi, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1073 · Cited by 512
Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation
Varela, I., Cadiñanos, J., Pendás, A. M., Gutiérrez-Fernández, A., Folgueras, A. R., Sánchez, L. M., Zhou, Z., Rodríguez, F. J., Stewart, C. L., Vega, J. A., et al. (2005) · Nature · doi:10.1038/nature04019 · Cited by 466
Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress
Amundson, S. A., Myers, T. G., & Fornace, A. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202576 · Cited by 424
A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation
Zhang, Y., & Xiong, Y. (2001) · Science · doi:10.1126/science.1058637 · Cited by 378
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A., & Rotter, V (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.12.6565 · Cited by 356
How p53 binds DNA as a tetramer
McLure, K. G., & Lee, P. W. K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3342 · Cited by 260
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212
MdmX Protects p53 from Mdm2-Mediated Degradation
Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211
Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look
Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 208
Comparative study of the p53-mdm2 and p53-MDMX interfaces
Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189
p53 and regulation of DNA damage recognition during nucleotide excision repair
Adimoolam, S., & Ford, J. M. (2003) · DNA Repair · doi:10.1016/s1568-7864(03)00087-9 · Cited by 181
Correcting temperature-sensitive protein folding defects
Brown, C. R., Hong-Brown, L. Q., & Welch, W. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119302 · Cited by 176
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Does p53 affect organismal aging?
Donehower, L. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10104 · Cited by 155
Core domain interactions in full-length p53 in solution
Veprintsev, D. B., Freund, S. M. V., Andreeva, A., Rutledge, S. E., Tidow, H., Cañadillas, J. M. P., Blair, C. M., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511130103 · Cited by 95
Li, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57
Research works printed but not linked: 287
- Chang C., 1979, J. Virol., 31, 463, 10.1128/jvi.31.2.463-471.1979 · DOI
- 10.1038/278261a0 · DOI · Paper page
- 10.1016/0092-8674(79)90293-9 · DOI · Paper page
- 10.1002/ijc.2910570102 · DOI · Paper page
- 10.1038/35042675 · DOI · Paper page
- 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
- 10.1093/emboj/17.7.1847 · DOI · Paper page
- 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.0.CO;2-H · doi:10.1002/(sici)1098-1004(1999)14:1<1::aid-humu1>3.0.co;2-h
- Jin S., 2001, J. Cell Sci., 114, 4139, 10.1242/jcs.114.23.4139 · DOI · Paper page
- 10.1038/35077213 · DOI · Paper page
- 10.1128/MCB.4.9.1689 · DOI · Paper page
- 10.1007/BF01534845 · doi:10.1007/bf01534845
- 10.1038/319783a0 · DOI · Paper page
- 10.1073/pnas.85.14.5146 · DOI
- Soussi T., 1990, Oncogene, 5, 945
- 10.1007/978-3-642-80481-6_1 · DOI
- 10.1038/sj.onc.1201263 · DOI · Paper page
- 10.1073/pnas.93.26.15335 · DOI · Paper page
- 10.1093/emboj/17.16.4668 · DOI · Paper page
- 10.1126/science.2144363 · DOI · Paper page
- 10.1073/pnas.92.11.5154 · DOI · Paper page
- 10.1126/science.7809597 · DOI · Paper page
- 10.1038/sj.onc.1203312 · DOI
- 10.1073/pnas.96.26.14801 · DOI
- 10.1128/jvi.69.3.1851-1859.1995 · DOI · Paper page
- 10.1126/science.281.5383.1674 · DOI · Paper page
- 10.1006/jmbi.2001.5082 · DOI
- 10.1016/S0022-2836(02)00848-3 · DOI · Paper page
- 10.1016/j.jmb.2003.08.008 · DOI · Paper page
- 10.1074/jbc.M003107200 · DOI · Paper page
- 10.1016/S1093-3263(00)00138-8 · DOI · Paper page
- 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7 · DOI · Paper page
- 10.1074/jbc.M508149200 · DOI
- 10.1101/gad.7.12b.2565 · DOI · Paper page
- 10.1101/gad.7.12b.2556 · DOI · Paper page
- 10.1016/0092-8674(92)90562-Q · DOI · Paper page
- 10.1128/MCB.14.8.5182 · DOI · Paper page
- Hainaut P., 1994, Oncogene, 9, 299
- 10.1021/bi00016a002 · DOI
- 10.1093/emboj/17.10.2748 · DOI
- 10.1038/5880 · DOI
- 10.1038/nsb0495-321 · DOI · Paper page
- 10.1038/nsb1294-877 · DOI · Paper page
- 10.1126/science.7878469 · DOI · Paper page
- 10.1016/j.jmb.2004.06.071 · DOI · Paper page
- 10.1006/jmbi.2001.4450 · DOI
- 10.1038/nsb0901-730 · DOI
- 10.1074/jbc.M107516200 · DOI · Paper page
- 10.1101/SQB.1994.059.01.024 · DOI
- 10.1016/0092-8674(95)90165-5 · DOI · Paper page
- 10.1128/MCB.17.11.6255 · DOI
- 10.1016/j.jmb.2004.07.042 · DOI · Paper page
- 10.1038/sj.onc.1203285 · DOI · Paper page
- 10.1016/j.str.2005.01.020 · DOI · Paper page
- 10.1128/MCB.4.9.1689 · DOI · Paper page
- 10.1074/jbc.271.7.3917 · DOI
- 10.1006/jmbi.1997.1507 · DOI
- 10.1074/jbc.M407687200 · DOI
- 10.1074/jbc.M407601200 · DOI
- 10.1021/bi011736r · DOI
- 10.1021/bi970759w · DOI · Paper page
- 10.1016/j.febslet.2004.07.014 · DOI
- 10.1073/pnas.132393699 · DOI
- 10.1074/jbc.M102817200 · DOI · Paper page
- 10.1074/jbc.M206697200 · DOI
- 10.1016/S0092-8674(00)80540-1 · DOI · Paper page
- 10.1016/S1097-2765(00)80275-0 · DOI · Paper page
- Moll U. M., 2004, Mol. Cancer Res., 2, 371, 10.1158/1541-7786.371.2.7 · DOI · Paper page
- 10.1016/j.tibs.2003.10.004 · DOI · Paper page
- 10.1038/nm0798-747 · DOI · Paper page
- 10.1016/S0168-9525(02)02595-7 · DOI · Paper page
- 10.1093/emboj/18.16.4438 · DOI · Paper page
- 10.1107/S0907444901002529 · DOI
- 10.1002/pro.5560060128 · DOI · Paper page
- 10.1074/jbc.M307846200 · DOI
- Lu H., 1999, FASEB J., 13, 1538
- 10.1038/sj.onc.1204427 · DOI · Paper page
- 10.1023/A:1024044805720 · DOI
- 10.1016/S0006-2952(03)00511-2 · DOI
- 10.4161/cbt.4.4.1619 · DOI
- 10.1016/j.ccr.2005.02.019 · DOI · Paper page
- 10.1038/416560a · DOI · Paper page
- 10.1016/S0092-8674(00)80627-3 · DOI · Paper page
- 10.1126/science.1065486 · DOI · Paper page
- 10.1073/pnas.97.13.7301 · DOI · Paper page
- 10.1016/S0092-8674(00)80626-1 · DOI · Paper page
- 10.1016/S0960-9822(01)00534-6 · DOI · Paper page
- 10.1038/35094077 · DOI · Paper page
- 10.1073/pnas.96.5.1875 · DOI
- 10.1073/pnas.92.19.8591 · DOI
- 10.1016/j.jmb.2005.03.014 · DOI · Paper page
- 10.1093/emboj/18.3.763 · DOI
- 10.1074/jbc.M103801200 · DOI
- 10.1016/S0022-2836(02)00326-1 · DOI · Paper page
- 10.1074/jbc.M011644200 · DOI
- 10.1002/ange.200501887 · DOI
- 10.1002/anie.200501887 · DOI
- 10.1101/SQB.1994.059.01.025 · DOI
- Arrowsmith C. H., 1996, Oncogene, 12, 1379
- 10.1093/protein/14.4.233 · DOI
- 10.1073/pnas.0500215102 · DOI
- 10.1073/pnas.90.8.3319 · DOI · Paper page
- 10.1074/jbc.M603634200 · DOI · Paper page
- Wang X., 1995, Cancer Epidemiol. Biomarkers Prev., 4, 543
- 10.1002/humu.10185 · DOI · Paper page
- 10.1038/sj.onc.1204468 · DOI
- 10.1074/jbc.M507611200 · DOI · Paper page
- 10.1126/science.1905840 · DOI · Paper page
- Hollstein M., 1994, Nucleic Acids Res., 22, 3551
- 10.1093/nar/25.1.151 · DOI · Paper page
- 10.1128/MCB.12.6.2866 · DOI · Paper page
- Sigal A., 2000, Cancer Res., 60, 6788
- 10.1093/nar/gki252 · DOI
- 10.1007/s000180050271 · DOI
- 10.1073/pnas.92.12.5729 · DOI
- 10.1016/S0968-0004(00)88954-9 · DOI
- 10.1038/sj.onc.1203434 · DOI · Paper page
- 10.1038/sj.onc.1202041 · DOI · Paper page
- 10.1016/S0955-0674(03)00003-6 · DOI · Paper page
- 10.1046/j.1432-1327.2001.02225.x · DOI · Paper page
- 10.1006/jmbi.1996.0560 · DOI
- 10.4161/cc.4.4.1598 · DOI · Paper page
- 10.1016/S0960-9822(00)00439-5 · DOI · Paper page
- 10.1038/sj.onc.1202480 · DOI · Paper page
- 10.1074/jbc.M410233200 · DOI · Paper page
- 10.1038/42972 · DOI · Paper page
- 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
- 10.1046/j.1432-1327.2001.02226.x · DOI · Paper page
- 10.1016/S0092-8674(01)00619-5 · DOI · Paper page
- 10.1016/S0092-8674(01)00524-4 · DOI · Paper page
- 10.1016/S0092-8674(01)00527-X · DOI · Paper page
- 10.1002/0470862637.ch14 · DOI
- 10.1038/nrm731 · DOI · Paper page
- 10.1074/jbc.275.12.8945 · DOI · Paper page
- 10.1038/35096061 · DOI · Paper page
- 10.1016/S1357-4310(98)01260-X · DOI
- 10.1038/nature737 · DOI · Paper page
- 10.1016/j.cell.2005.03.037 · DOI · Paper page
- 10.1038/nature02514 · DOI · Paper page
- 10.1016/S0092-8674(03)00193-4 · DOI · Paper page
- 10.1016/j.cell.2005.06.018 · DOI
- 10.1093/emboj/18.22.6455 · DOI · Paper page
- 10.1093/emboj/18.22.6462 · DOI · Paper page
- 10.4161/cc.1.4.131 · DOI
- 10.1016/j.cell.2004.06.015 · DOI
- 10.1016/j.cell.2004.06.016 · DOI · Paper page
- Shaw P., 1996, Oncogene, 12, 921
- 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J · doi:10.1002/(sici)1097-4644(199607)62:1<90::aid-jcb10>3.0.co;2-j
- 10.1073/pnas.0308762101 · DOI · Paper page
- 10.1038/nrc864 · DOI · Paper page
- 10.1093/nar/26.15.3453 · DOI · Paper page
- 10.1007/BF03402141 · DOI · Paper page
- 10.1007/BF03401678 · DOI
- Picksley S. M., 1994, Oncogene, 9, 2523
- 10.1128/MCB.13.7.4107 · DOI · Paper page
- 10.1073/pnas.96.26.14801 · DOI
- 10.1016/S0022-2836(02)00852-5 · DOI · Paper page
- 10.1016/j.jmb.2003.11.051 · DOI
- 10.1073/pnas.0334477100 · DOI
- 10.1093/embo-reports/kve227 · DOI · Paper page
- 10.1016/j.bbrc.2005.03.151 · DOI · Paper page
- 10.1016/j.jmb.2005.05.010 · DOI
- 10.1023/B:JNMR.0000048856.84603.9b · DOI
- 10.1007/PL00012484 · doi:10.1007/pl00012484
- 10.1002/1521-3757(20020402)114:7<1142::AID-ANGE1142>3.0.CO;2-T · DOI
- 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9 · DOI · Paper page
- 10.1146/annurev.cb.09.110193.003125 · DOI · Paper page
- 10.1016/S0092-8674(00)80928-9 · DOI · Paper page
- 10.1016/j.molcel.2005.09.028 · DOI · Paper page
- 10.1126/science.2188360 · DOI · Paper page
- 10.1038/370111a0 · DOI · Paper page
- 10.1146/annurev.bi.62.070193.002025 · DOI · Paper page
- 10.1093/emboj/18.24.6934 · DOI · Paper page
- 10.1007/s10254-003-0021-1 · DOI · Paper page
- Hupp T. R., 2000, Biochem. J., 1, 10.1042/bj3520001 · DOI
- 10.1093/emboj/20.22.6297 · DOI · Paper page
- 10.1016/0014-5793(94)01417-Y · DOI
- 10.1093/emboj/20.17.4634 · DOI · Paper page
- 10.1074/jbc.M100200200 · DOI
- 10.1046/j.1365-2184.2000.00189.x · DOI · Paper page
- 10.1074/jbc.274.39.27474 · DOI
- 10.1128/MCB.16.3.1126 · DOI · Paper page
- 10.1128/MCB.4.12.2802 · DOI · Paper page
- 10.1016/S0021-9258(18)33376-3 · DOI · Paper page
- 10.1074/jbc.272.30.18608 · DOI
- 10.1073/pnas.93.16.8379 · DOI · Paper page
- 10.1074/jbc.271.25.15084 · DOI
- 10.1128/MCB.18.3.1517 · DOI · Paper page
- 10.1038/sj.onc.1202978 · DOI
- 10.1016/S0014-5793(99)00505-0 · DOI
- 10.1093/emboj/20.4.914 · DOI · Paper page
- 10.1074/jbc.275.21.16202 · DOI · Paper page
- 10.1002/path.1704 · DOI
- 10.1016/j.mrfmmm.2004.08.022 · DOI
- 10.1016/j.ceb.2005.09.007 · DOI · Paper page
- 10.1378/chest.125.5_suppl.83S-a · DOI
- 10.1093/emboj/cdf595 · DOI · Paper page
- Kastan M. B., 1991, Cancer Res., 51, 6304
- 10.1101/gad.8.21.2540 · DOI · Paper page
- Linke S. P., 1997, Cancer Res., 57, 1171
200 of 287 shown
Cited by
Galliford, C. V., & Scheidt, K. A. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200701342 · Cited by 2,429
Natürliche Pyrrolidinylspirooxindole als Vorlagen für die Entwicklung medizinischer Wirkstoffe
Galliford, C. V., & Scheidt, K. A. (2007) · Angewandte Chemie · doi:10.1002/ange.200701342 · Cited by 524
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain
Wells, M., Tidow, H., Rutherford, T. J., Markwick, P., Jensen, M. R., Mylonas, E., Svergun, D. I., Blackledge, M., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801353105 · Cited by 434
Metal-NHC complexes: a survey of anti-cancer properties
Teyssot, M.-L., Jarrousse, A.-S., Manin, M., Chevry, A., Roche, S., Norre, F., Beaudoin, C., Morel, L., Boyer, D., Mahiou, R., et al. (2009) · Dalton Transactions · doi:10.1039/b906308k · Cited by 384
The Tumor Suppressor p53: From Structures to Drug Discovery
Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 357
Metadata
- Authors
- Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2006-09-29
- Volume
- 45
- Issue
- 39
- Pages
- 6440-6460
- ISSN
- 1433-7851
- 1521-3773
- Cited by
- 93
- References
- 44
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.